· Журналы · Книги · О проекте ·Электронные версии книг издательства “Атмосфера” поступили в продажу Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru ИНТЕРНЕТ-МАГАЗИН    Атмосфера. Новости кардиологии 2003 / N 3 Гиполипидемические средства при лечении больных сахарным диабетом 2-го типа: новые данные (Список литературы) А.В. Сусеков Список литературы 1. Hayden JM, Reaven PD. Cardiovascular disease in diabetes mellitus type 2:a potential role for novel cardiovascular cardiovascular risk-factors. Curr Opin Lipidol 2000; 11:19-28. 2. James RW. Diabetes and other coronary heart diasese risk equivalents. Current Opinion in Lipidology 2001;12:425-431. 3. Betteridge DJ. Lipid-lowering trials in diabetes. Current Opinion in Lipidology. 2001, 12:619-623. 4. Lehto S, Ronnemaa T, Pyorala K, Laakso M. Cardiovascular risk factros clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with type II diabetes. Diabetologia 2000;43:148-155. 5. Pyorala M, Miettinen H, Halonen P et al. Insulin resistance syndrome predicts the risk of coronary heart disaese and stroke in healthy middle-aged men: the Kuopio Ischemic Heart Disease Risk Factor Study . Arch Intern Med 2000;160:1160-1168. 6. Diabetes Statistics. National Diabetes Information Clearinghouse . Bethesda, Md: National Institute of Diabetes and Digestive and kidney Diseases, NIH publication 99-3926.1999. 7. Pyorala K, Laakso M et al. Diabetes and atherosclerosis: an epidemiological view. Diabetes Metab. Rev. 1987;3:463-524. 8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285(19): 2486-2497. 9. King H, Aubert RE, Herman WH/ Global burden of diabetes, 1995-2025:prevalence, numerical estimates and projections. Diabetes Care 1998;21:1414-31. 10. UK Prospective Diabetes Study Group. UK Prospective Study:plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care. 1997, 20(11), 1663-1687. 11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonyrureas or insulin compared with conventional treatment and risk of complications in plasma with type 2 diabetes (UKPDS 33). Lancet 1998, 352. 316-318. 12. Turner R, Milns H, Neil H et al. for the United Kigdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus. United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ 1998;316, 823-828. 13. Сусеков А. В., Кухарчук В.В. Гипертриглицеридемия как фактор риска развития атеросклероза. Терапевтический архив, 1997, № 9, 83-88. 14. Golay A. Are postprandial triglyceride and insulin abnormalities neglected cardiovascular risk-factors in type 2 diabetes ? Eur. J. Clin. Invest. 2000; 30( Suppl. 2): 12-18. 15. Teno S, Uto Y, Nagashima H et al. Association of postprandial hypertriglyceridaemia and carotid intima-media thickness in patients with type 2 diabetes. Diabetes Care 2000;23:1401-1406. 16. Haffner SM, Agostino RD, Saad MF et al. Carotid artery atherosclerosis in type 2 diabetic and nondiabetic subjects with and without symptomatic coronary artery disease (The Insulin Resistance Atherosclerosis Study). Am. J. Cardiology 2000;85:1395-4000. 17. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet 2001;357:905-910. 18. Goldberg RB, Mellies MJ, Sacks FM, Lemuel AM et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 1998;2513-2519. 19. Pyorala K, Pedersen TR, Kjeksus J, Faergeman O, Olsson AG et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-620. 20. The long-term prevention with pravastatin in ischemic disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 1998;339:1349-1357. 21. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beer PA et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels . JAMA 1998; 279:1615-1622. 22. Shepherd J, Blauw GJ, Murphy MB, Bollen E et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002;360:1623- 1630. 23. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in moderately hypercholesterolemic, hypertensive patients randomized to Pravastatin vs Usual Care. The antihypertensive and lipid-lowering treatment to prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288 (23):2898-3007. 24. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB et al. for the Veterans Affaires High -Density Lipoprotein Cholesterol Intervention Trial Study Group.Gemfibrozil for the Secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N. Engl. J. Med. 1999; 341:410-418. 25. Robins SJ. Current Opinion in Endocrinology and Diabetes, 2002;9:312-322. 26. Collins R. Heart Protection Study-Main results. Late-breaking clinical trails. American Heart Association. Scientific Sessions 2001. 13 November 2001. Anahaim. California. USA. 27. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk patients: a randomized placebo-controlled trial.Lancet 2002; 360:7-22. 28. Сусеков АВ, Зубарева МЮ, Кухарчук ВВ. Heart Protection Study - Исследование Защиты Сердца (по материалам симпозиума). Клин фармакология и терапия. 2002, 1;71-74. 29. Сусеков А В . Исследование Защиты Сердца -новые стандарты в лечении атеросклероза. Атмосфера Кардиология. 2002; 2(3):14-16. 30. Сусеков А .В. Практические аспекты "Исследования Защиты Сердца". Терапевтический архив 2003, в печати. 31. Heart Protection Study Group.MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003;361:2005-16. 32. The Heart Otcomes Prevention Evaluation Study Investigators . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl. J. Med. 2000;342:145-53.    [ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]